Form 6K Alvotech SA For: 6 January
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alvotech SA (ALVO)
Alvotech SA stock price live, this page displays NASDAQ ALVO stock exchange data. View the ALVO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Alvotech SA real time stock price chart below.
What Is the Alvotech SA Stock Price Today?
The Alvotech SA stock price today is 4.92.
What Is the Stock Symbol for Alvotech SA?
The stock symbol for Alvotech SA is "ALVO."
What Stock Exchange Does Alvotech SA Trade On?
Alvotech SA is listed and trades on the NASDAQ stock exchange.
Is Alvotech SA a Good Stock to Buy?
Determining whether Alvotech SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALVO quote. (ISIN: LU2458332611)
What Is the Alvotech SA Stock Price Today?
The Alvotech SA stock price today is 4.92.
What Is the Stock Symbol for Alvotech SA?
The stock symbol for Alvotech SA is "ALVO."
What Stock Exchange Does Alvotech SA Trade On?
Alvotech SA is listed and trades on the NASDAQ stock exchange.
Is Alvotech SA a Good Stock to Buy?
Determining whether Alvotech SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALVO quote. (ISIN: LU2458332611)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.86
5.01
52 wk Range
4.32
13.44
ALVO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.865.01
52 wk Range
4.3213.44
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALVO Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
22.17
Upside
+350.54%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
- Form 6K Alvotech SA For: 23 December
- Investing.com
- Form 6K Alvotech SA For: 6 January
- Investing.com
- Form 6K Alvotech SA For: 2 January
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Neutral
Moving Averages
Strong Buy
Alvotech SA Company Profile
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn’s disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Alvotech SA SWOT Analysis
Biosimilar Pionee | Alvotech emerges as a potential top-3 global biosimilars pureplay, leveraging a unique B2B model in a competitive pharmaceutical landscape |
Financial Trajectory | Despite current negative EPS, Alvotech projects strong growth with Q3 2024 revenue forecast at $93 million and positive EPS expected in the second fiscal yea |
Product Portfolio | Explore Alvotech's key products Simlandi and Selardsi, alongside three upcoming BLA filings, driving the company's market expansion and revenue growth strategies |
Market Valuation | Analysts maintain an $18 price target, reflecting confidence in Alvotech's long-term potential despite current profitability challenges and market uncertainties |
Alvotech SA Earnings Call Summary for Q3/2025
- Alvotech reported Q3 2025 EPS of $0.47, missing the -$0.03 forecast by -1666.67%, with revenue of $114M slightly below expectations, causing a 4.29% stock decline.
- Despite Q3 challenges, the company achieved 24% year-on-year revenue growth for the first nine months of 2025, reaching $420M with adjusted EBITDA of $68M.
- Management revised full-year guidance to $570-600M in revenue and $130-150M in adjusted EBITDA, projecting 19% revenue growth and 30% EBITDA increase.
- CEO Róbert Wessman highlighted $2B investment in building a global biosimilar company, with new product launches planned in Europe for Eylea, Simponi, and Prolia/Xgeva.
- The company faces regulatory challenges, including an FDA Complete Response Letter for its Simponi biosimilar, though it has completed 93% of FDA observation commitments.
Last Updated: 2025-11-13, 09:26 a/m
Read Full TranscriptCompare ALVO to Peers and Sector
Metrics to compare | ALVO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALVOPeersSector | |
|---|---|---|---|---|
P/E Ratio | 22.2x | −2.2x | −0.6x | |
PEG Ratio | 0.19 | 0.10 | 0.00 | |
Price/Book | −8.7x | 4.1x | 2.6x | |
Price / LTM Sales | 2.7x | 5.8x | 3.4x | |
Upside (Analyst Target) | 103.3% | 150.8% | 41.1% | |
Fair Value Upside | Unlock | 14.1% | 5.3% | Unlock |
Analyst Ratings
4 Buy
1 Hold
1 Sell
Ratings:
6 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 22.17
(+350.54% Upside)
Earnings
Latest Release
Nov 12, 2025
EPS / Forecast
0.47 / -0.03
Revenue / Forecast
114.00M / 115.20M
People Also Watch
FAQ
What Is the Alvotech (ALVO) Stock Price Today?
The Alvotech stock price today is 4.92
What Stock Exchange Does Alvotech Trade On?
Alvotech is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Alvotech?
The stock symbol for Alvotech is "ALVO."
What Is the Alvotech Market Cap?
As of today, Alvotech market cap is 1.54B.
What Is Alvotech's Earnings Per Share (TTM)?
The Alvotech EPS (TTM) is 0.24.
When Is the Next Alvotech Earnings Date?
Alvotech will release its next earnings report on Mar 18, 2026.
From a Technical Analysis Perspective, Is ALVO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Alvotech Stock Split?
Alvotech has split 0 times.
How Many Employees Does Alvotech Have?
Alvotech has 1012 employees.
What is the current trading status of Alvotech (ALVO)?
As of Jan 17, 2026, Alvotech (ALVO) is trading at a price of 4.92, with a previous close of 4.95. The stock has fluctuated within a day range of 4.86 to 5.01, while its 52-week range spans from 4.32 to 13.44.
What Is Alvotech (ALVO) Price Target According to Analysts?
The average 12-month price target for Alvotech is USD22.16667, with a high estimate of USD90 and a low estimate of USD5. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +350.54% Upside potential.
What Is the ALVO Premarket Price?
ALVO's last pre-market stock price is 4.85. The pre-market share volume is 1,130.00, and the stock has decreased by -0.10, or -2.02%.
What Is the ALVO After Hours Price?
ALVO's last after hours stock price is 4.95, the stock has decreased by 0.03, or 0.61%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.